FFA
AARD

Farther Finance Advisors’s Aardvark Therapeutics AARD Stock Holding History

Farther Finance Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867 Buy
153
+125
+446% +$584 ﹤0.01% 5410
2026
Q1 		$115 Buy
+28
New +$290 ﹤0.01% 5497

Other funds holding AARD

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Farther Finance Advisors's AARD Position: Q2 2026 in Review

Farther Finance Advisors increased its Aardvark Therapeutics (AARD) stake by 446% in Q2 2026, buying an estimated $584 and bringing the position to 153 shares worth $867. The position accounts for ﹤0.01% of the portfolio, ranked #5410.

Farther Finance Advisors first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Farther Finance Advisors held 153 shares of Aardvark Therapeutics worth $867 as of Q2 2026.
  • Farther Finance Advisors bought 125 Aardvark Therapeutics shares in Q2 2026, an estimated $584.
  • Aardvark Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5410 holding.
  • Farther Finance Advisors first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.